Loading...
Market
What will be the effectiveness of MED6-189 in Phase I clinical trial results by June 30, 2025?
2
Resolution / Starting Odds
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
ClinicalTrials.gov and scientific journals
Story
Kalihinol Analog MED6-189 Shows Promise Against Drug-Resistant Malaria Parasite
Sep 27, 2024, 07:28 AM
A synthetic compound, MED6-189, a kalihinol analog, has shown promise against both drug-sensitive and drug-resistant strains of the malaria parasite Plasmodium falciparum. The compound disrupts apicoplast function and vesicular trafficking in the parasite, effectively killing it. This discovery, highlighted in a study published in Science, demonstrated efficacy in a humanized mouse model of malaria. Research by @UCRiverside and @ScienceMagazine indicates that MED6-189 could be a significant advancement in the fight against malaria.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%